MARKET

ELDN

ELDN

Eledon Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.570
-0.080
-2.19%
Closed 16:00 05/27 EDT
OPEN
3.690
PREV CLOSE
3.650
HIGH
3.748
LOW
3.397
VOLUME
36.30K
TURNOVER
78.15K
52 WEEK HIGH
9.90
52 WEEK LOW
2.270
MARKET CAP
49.11M
P/E (TTM)
-1.4609
1D
5D
1M
3M
1Y
5Y
Eledon Pharma: Q1 Earnings Insights
Eledon Pharma (NASDAQ:ELDN) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Eledon Pharma missed estimated earnings by 1.47%, reporting an EPS of $-0.69 versus an e...
Benzinga · 05/12 21:04
BRIEF-Eledon Pharmaceuticals Reports Q1 2022 Operating And Financial Results
reuters.com · 05/12 20:56
Eledon Pharmaceuticals Q1 EPS $(0.69) Misses $(0.68) Estimate
Eledon Pharmaceuticals (NASDAQ:ELDN) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.68) by 1.47 percent. This is a 21.05 percent decrease over losses of $(0.57) per
Benzinga · 05/12 20:17
Eledon Pharmaceuticals GAAP EPS of -$0.69
Eledon Pharmaceuticals press release (NASDAQ:ELDN): Q1 GAAP EPS of -$0.69. The company had approximately $76.7M in cash and cash equivalents as of Mar. 31.
Seekingalpha · 05/12 20:04
Earnings Outlook For Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Eledon Pharmaceuticals will report an earnings per share (E...
Benzinga · 05/11 17:04
Eledon begins dosing in phase 2a study of tegoprubart to treat kidney disease
Eledon Pharmaceuticals (NASDAQ:ELDN) said the first patient was dosed in a phase 2a trial of tegoprubart to treat patients with IgA Nephropathy (IgAN). IgAN is a type of kidney disease which
Seekingalpha · 05/09 13:37
Eledon Pharmaceuticals Announces First Patient Dosed In Phase 2a Trial Evaluating Tegoprubart In IgA Nephropathy
Initial data from open label Phase 2a study expected in late 2022 IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a patient-focused clinical stage
Benzinga · 05/09 12:14
Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Management to host conference call and webcast at 4:30 p.m. ETIRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development o...
GlobeNewswire · 05/05 20:05
More
No Data
Learn about the latest financial forecast of ELDN. Analyze the recent business situations of Eledon Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ELDN stock price target is 26.80 with a high estimate of 39.00 and a low estimate of 15.00.
High39.00
Average26.80
Low15.00
Current 3.570
EPS
Actual
Estimate
-0.60-0.45-0.30-0.15
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 44
Institutional Holdings: 7.69M
% Owned: 55.90%
Shares Outstanding: 13.76M
TypeInstitutionsShares
Increased
8
1.22M
New
1
27.60K
Decreased
8
245.24K
Sold Out
6
1.88M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Keith Katkin
President/Chief Scientific Officer/Director
Steven Perrin
Chief Executive Officer/Director
David-Alexandre Gros
Chief Financial Officer
Paul Little
Chief Compliance Officer/General Counsel/Secretary
Bryan Smith
Other
Jeff Bornstein
Other
David Hovland
Independent Director
Jan Hillson
Independent Director
June Lee
Independent Director
Gary Lyons
Independent Director
John McBride
Independent Director
Walter Ogier
No Data
No Data
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for persons living with an autoimmune disease, which requires an organ or cell-based transplant or living with amyotrophic lateral sclerosis (ALS). The Company's lead product candidate, AT-1501, is a humanized monoclonal antibody (mAb) designed to target CD40 Ligand (CD40L) also called CD154), a molecule expressed on the surface of human immune system T cells. The central role of CD40 or CD40L signaling in generating pro-inflammatory responses makes it a candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance and neuroinflammation. Blocking the activation of the CD40L pathway prevents acute and long-term allograft transplant rejection in multiple animal species and ameliorates disease progression and pathology in preclinical models of autoimmunity and ALS.

Webull offers kinds of Eledon Pharmaceuticals Inc stock information, including NASDAQ:ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.